These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 37006130)
41. Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders. Papola D; Ostuzzi G; Todesco B; Gastaldon C; Hanna F; Chatterjee S; van Ommeren M; Barbui C Lancet Psychiatry; 2023 Oct; 10(10):809-816. PubMed ID: 37475123 [TBL] [Abstract][Full Text] [Related]
42. Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned? Osorio-de-Castro CGS; Azeredo TB; Pepe VLE; Lopes LC; Yamauti S; Godman B; Gustafsson LL Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):402-412. PubMed ID: 29117642 [TBL] [Abstract][Full Text] [Related]
43. WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines. Jenei K; Glaus CEG; Vokinger KN Lancet; 2024 Oct; 404(10460):1365-1374. PubMed ID: 39368844 [TBL] [Abstract][Full Text] [Related]
44. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists. Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK PLoS One; 2014; 9(9):e106072. PubMed ID: 25259517 [TBL] [Abstract][Full Text] [Related]
45. Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province. Matlala M; Gous AGS; Meyer JC; Godman B Front Pharmacol; 2020; 11():1267. PubMed ID: 32973508 [TBL] [Abstract][Full Text] [Related]
46. Essential medicines for cancer: WHO recommendations and national priorities. Robertson J; Barr R; Shulman LN; Forte GB; Magrini N Bull World Health Organ; 2016 Oct; 94(10):735-742. PubMed ID: 27843163 [TBL] [Abstract][Full Text] [Related]
47. [The essentiality and rationality of the Brazilian national listing of essential medicines]. Yamauti SM; Bonfim JR; Barberato-Filho S; Lopes LC Cien Saude Colet; 2017 Mar; 22(3):975-986. PubMed ID: 28301004 [TBL] [Abstract][Full Text] [Related]
48. Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan. Saqib A; Iftikhar S; Sarwar MR BMJ Open; 2018 Jun; 8(6):e019015. PubMed ID: 29903783 [TBL] [Abstract][Full Text] [Related]
49. [Valor terapéutico potencial de medicamentos en México: el caso de los antibióticos]. Mino-León D; Hernández-Carvajal I; Peredo-Silva L; Búrbano-Martínez G Gac Med Mex; 2019; 155(1):15-19. PubMed ID: 30799460 [TBL] [Abstract][Full Text] [Related]
50. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO. Piggott T; Nowak A; Brignardello-Petersen R; Cooke GS; Huttner B; Schünemann HJ; Persaud N; Magrini N; Moja L BMJ Open; 2022 Feb; 12(2):e053349. PubMed ID: 35144950 [TBL] [Abstract][Full Text] [Related]
51. Availability of brands of six essential medicines in 124 pharmacies in Maharashtra. Millard C; Kadam AB; Mahajan R; Pollock AM; Brhlikova P J Glob Health; 2018 Jun; 8(1):010402. PubMed ID: 29423188 [TBL] [Abstract][Full Text] [Related]
52. Comparison of essential medicines lists in 137 countries. Persaud N; Jiang M; Shaikh R; Bali A; Oronsaye E; Woods H; Drozdzal G; Rajakulasingam Y; Maraj D; Wadhawan S; Umali N; Wang R; McCall M; Aronson JK; Plüddemann A; Moja L; Magrini N; Heneghan C Bull World Health Organ; 2019 Jun; 97(6):394-404C. PubMed ID: 31210677 [TBL] [Abstract][Full Text] [Related]
53. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. Chen W; Tang S; Sun J; Ross-Degnan D; Wagner AK BMC Health Serv Res; 2010 Jul; 10():211. PubMed ID: 20637116 [TBL] [Abstract][Full Text] [Related]
54. Essential Medicines in a High Income Country: Essential to Whom? Duong M; Moles RJ; Chaar B; Chen TF; PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544 [TBL] [Abstract][Full Text] [Related]
55. A national survey on registered products, availability, prices, and affordability of 100 essential medicines in community pharmacies across Sri Lanka. Liyanage CK; Gunawardane M; Kumaradasa PP; Ranasinghe P; Jayakody RL; Galappatthy P BMC Health Serv Res; 2023 Oct; 23(1):1121. PubMed ID: 37858145 [TBL] [Abstract][Full Text] [Related]
56. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain. Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862 [TBL] [Abstract][Full Text] [Related]
57. Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana. Mensah KB; Mensah ABB; Bangalee V; Padayachee N; Oosthuizen F BMC Cancer; 2021 Jun; 21(1):683. PubMed ID: 34112117 [TBL] [Abstract][Full Text] [Related]
58. Essential psychiatric medicines: wrong selection, high consumption and social problems. Fulone I; Barberato-Filho S; dos Santos MF; Rossi Cde L; Guyatt G; Lopes LC BMC Public Health; 2016 Jan; 16():52. PubMed ID: 26792369 [TBL] [Abstract][Full Text] [Related]
59. Expanding medicines for neurologic disorders on the WHO Model List. Rimmer K; Shah H; Thakur K Neurology; 2017 Mar; 88(10):e87-e91. PubMed ID: 28265046 [TBL] [Abstract][Full Text] [Related]
60. Global, regional and national availability of essential medicines for children, 2009-2020: a systematic review and meta-analysis. Shi Y; Chen Z; Zou K; Zhang M; Liu Z; Liu D; Zeng L; Li H; Jia ZJ; Cheng G; Tang Y; Zhao S; Jiang Y; Choonara I; Zhang L BMC Public Health; 2023 Jun; 23(1):1185. PubMed ID: 37340382 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]